The 10 year Shingrix data showing continued humoral responses in "normal" patients, with continued long-term efficacy (drops to only 70+%) suggesting we may need to boost at some point. In our rheumatology patients, the efficacy does drop and needs to be evaluated. Dr. Kevin… https://t.co/eHfjtsPv2O https://t.co/K1i5R3ZScV